Haemophilus b conjugate vaccine Intramuscular and Ropinirole Hydrochloride

• Generic Name: haemophilus b conjugate (prp-t) vaccine
• Dosage Forms: n.a.
• Other Brand Names: ActHIB, Hiberix

Haemophilus b conjugate vaccine is an active immunizing agent that is used to prevent infection caused by the Haemophilus influenza type b (Hib) bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.

Haemophilus b conjugate vaccine is prepared by adding a diphtheria, meningococcal, or tetanus-related substance to the process. However, this vaccine does not take the place of the regular vaccines for diphtheria, tetanus, or meningococcus that children and adults should receive. All of the haemophilus b conjugate vaccines work the same way, but they may be given at different ages or using a different schedule.

Infections with Haemophilus influenza type b (Hib) bacteria can cause life-threatening illnesses, such as meningitis (a brain disease), epiglottitis (a throat disease that can cause suffocation), pericarditis (a heart disease), pneumonia (a lung disease), and septic arthritis (a bone and joint disease). Hib meningitis may cause death or leave the child with serious and permanent damage, such as mental retardation, deafness, epilepsy, or partial blindness.

Haemophilus b conjugate vaccine is recommended for all children 2 months to 5 years of age (i.e., up to the 6th birthday).

The Hiberix® vaccine is used as a booster dose for children who have already received the primary series with a haemophilus b conjugate vaccine. The vaccine will "boost" or increase the protection that the child had from an earlier dose.

This vaccine is to be administered only by or under the direct supervision of your doctor.

• Generic Name: ropinirole
• Dosage Forms: n.a.
• Other Brand Names: Requip, Requip XL, ReQuip Follow on Pack, ReQuip Starter Pack, Repreve, Requip Starter Kit

Symptomatic management of idiopathic parkinsonian syndrome.

Used as an adjunct to levodopa for the symptomatic management of parkinsonian syndrome in patients with advanced disease.

Also used as monotherapy for the initial symptomatic management of parkinsonian syndrome. Most clinicians would use levodopa for initial therapy in individuals >70 years of age (less likely than younger individuals to develop levodopa-related motor complications and because of concerns about cognitive dysfunction), in patients with cognitive impairment, and in those with severe disease. A dopamine receptor agonist may be preferred for initial therapy in patients ≤70 years of age.

Symptomatic management of moderate-to-severe primary restless legs syndrome (Ekbom syndrome).